What's new in psoriasis treatment? An analysis of systematic reviews published in 2015

Abstract

This review provides a summary of key findings from 27 systematic reviews of 51 articles first published or indexed during 2015, focusing on the treatment of psoriasis and on precision medicine in psoriasis. The evidence supports weight-loss interventions by dieting and exercise for improvement in disease severity in overweight and obese patients with psoriasis. No significant increased risk of serious infections was reported for the biologic therapies adalimumab, etanercept and ustekinumab compared with appropriate comparators. Evidence could not provide reliable estimates of rare adverse events, emphasizing the need for large prospective registries. Polymorphisms in the tumour necrosis factor (TNF)-α gene may confer improved responses to TNF inhibitor (TNFI) therapy, but the studies to date lack power to detect a true association. From the limited available evidence, multidisciplinary management is both more effective and more satisfactory for patients with psoriasis and psoriatic arthritis than conventional consultations. This summary of reviews provides a succinct guide for clinicians and patients wishing to remain up to date with high-quality evidence for the treatment of psoriasis.

Visualising the past to plan the future: a network analysis of the largest European dermatology conference

“…It is likely that this trend was associated with novel insights into the pathomechanisms of these diseases which is underlined by the respective comparisons with the number of PubMed publications. Naturally, as new medications in these fields are emerging [18,19], conferences serve to instruct European clinicians. However, there seemed to be a regional disparity as contributors from Western Europe provided substantially more lectures compared to their colleagues from Eastern Europe.…”

A network analysis of the EADV 2019 conference

“…Network analysis of the EADV 2019 revealed several clusters of main interests with contributors from cities around the world. In particular, the focus was patient‐centred and lies on therapeutic approaches which is likely as new medications in these fields are emerging 10 and as the EADV congress serves to instruct European clinicians. The network analysis supplied an overview of what the European dermatologic community focused on at the EADV 2019 in Madrid.…”